A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates

详细信息    查看全文

• 作者：Hsin-Wei Chen (1) (2)
  Shih-Jen Liu (1) (2)
  Yi-Shiuan Li (1)
  Hsueh-Hung Liu (1)
  Jy-Ping Tsai (1)
  Chen-Yi Chiang (1)
  Mei-Yu Chen (1)
  Chyi-Sing Hwang (3)
  Chin-Cheng Huang (3)
  Hui-Mei Hu (1)
  Han-Hsuan Chung (1)
  Sze-Hsien Wu (1)
  Pele Chong (1)
  Chih-Hsiang Leng (1) (2)
  Chien-Hsiung Pan (1) (2)
  
• 刊名：Archives of Virology
• 出版年：2013
• 出版时间：July 2013
• 年：2013
• 卷：158
• 期：7
• 页码：1523-1531
• 全文大小：287KB
• 参考文献：1. Ashour J, Laurent-Rolle M, Shi PY, Garcia-Sastre A (2009) NS5 of dengue virus mediates STAT2 binding and degradation. J Virol 83:5408鈥?418 CrossRef
  2. Blaney JE, Matro JM, Murphy BR, Whitehead SS (2005) Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 79:5516鈥?528 CrossRef
  3. Chambers TJ, Hahn CS, Galler R, Rice CM (1990) Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 44:649鈥?88 CrossRef
  4. Chen HW, Liu SJ, Liu HH, Kwok Y, Lin CL, Lin LH, Chen MY, Tsai JP, Chang LS, Chiu FF, Lai LW, Lian WC, Yang CY, Hsieh SY, Chong P, Leng CH (2009) A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design. Vaccine 27:1400鈥?409 CrossRef
  5. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, Marks RM (1997) Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 3:866鈥?71 CrossRef
  6. Cheng HJ, Lei HY, Lin CF, Luo YH, Wan SW, Liu HS, Yeh TM, Lin YS (2009) Anti-dengue virus nonstructural protein 1 antibodies recognize protein disulfide isomerase on platelets and inhibit platelet aggregation. Mol Immunol 47:398鈥?06 CrossRef
  7. Chiang CY, Liu SJ, Tsai JP, Li YS, Chen MY, Liu HH, Chong P, Leng CH, Chen HW (2011) A novel single-dose dengue subunit vaccine induces memory immune responses. PLoS One 6:e23319 CrossRef
  8. Chiang CY, Huang MH, Hsieh CH, Chen MY, Liu HH, Tsai JP, Li YS, Chang CY, Liu SJ, Chong P, Leng CH, Chen HW (2012) Dengue-1 envelope protein domain III along with PELC and CpG oligodeoxynucleotides synergistically enhances immune responses. PLoS Negl Trop Dis 6:e1645 CrossRef
  9. Clements DE, Coller B-AG, Lieberman MM, Ogata S, Wang G, Harada KE, Putnak JR, Ivy JM, McDonell M, Bignami GS, Peters ID, Leung J, Weeks-Levy C, Nakano ET, Humphreys T (2010) Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 28:2705鈥?715 CrossRef
  10. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE Jr, de Silva AM (2012) Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA 109:7439鈥?444 CrossRef
  11. Glenny AT, BGA H, SM F (1931) Rate of disappearance of diphtheria toxoid injected into rabbits and guinea-pigs: toxoid precipitated with alum. J Pathol Bacteriol 34:12
  12. Gubler DJ, Kuno G, Markoff L (2007) Flaviviruses, 5th edn. Lippincott Williams & Wilkins, Philadelphia
  13. Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, Arroyo J, Georgakopoulos K, Catalan J, Monath TP (2000) Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 74:5477鈥?485 CrossRef
  14. Guy B, Barban V, Mantel N, Aguirre M, Gulia S, Pontvianne J, Jourdier TM, Ramirez L, Gregoire V, Charnay C, Burdin N, Dumas R, Lang J (2009) Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 80:302鈥?11
  15. Guzman MG, Rodriguez R, Hermida L, Alvarez M, Lazo L, Mune M, Rosario D, Valdes K, Vazquez S, Martinez R, Serrano T, Paez J, Espinosa R, Pumariega T, Guillen G (2003) Induction of neutralizing antibodies and partial protection from viral challenge in / Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in / Pichia pastoris. Am J Trop Med Hyg 69:129鈥?34
  16. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, Hunsperger E, Kroeger A, Margolis HS, Martinez E, Nathan MB, Pelegrino JL, Simmons C, Yoksan S, Peeling RW (2010) Dengue: a continuing global threat. Nat Rev Microbiol 8:S7鈥?6 CrossRef
  17. Halstead SB (1989) Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev Infect Dis 11(Suppl 4):S830鈥揝839 CrossRef
  18. Henchal EA, Gentry MK, McCown JM, Brandt WE (1982) Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am J Trop Med Hyg 31:830鈥?36
  19. Hermida L, Bernardo L, Martin J, Alvarez M, Prado I, Lopez C, Sierra Bde L, Martinez R, Rodriguez R, Zulueta A, Perez AB, Lazo L, Rosario D, Guillen G, Guzman MG (2006) A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24:3165鈥?171 CrossRef
  20. Huang KJ, Yang YC, Lin YS, Huang JH, Liu HS, Yeh TM, Chen SH, Liu CC, Lei HY (2006) The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J Immunol 176:2825鈥?832
  21. Innis BL (1997) Antibody responses to dengue virus infection. CAB International, New York
  22. Konishi E, Kosugi S, Imoto J (2006) Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 24:2200鈥?207 CrossRef
  23. Kyle JL, Harris E (2008) Global spread and persistence of dengue. Annu Rev Microbiol 62:71鈥?2 CrossRef
  24. Lai CY, Tsai WY, Lin SR, Kao CL, Hu HP, King CC, Wu HC, Chang GJ, Wang WK (2008) Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 82:6631鈥?643 CrossRef
  25. Leng C-H, Liu S-J, Tsai J-P, Li Y-S, Chen M-Y, Liu H-H, Lien S-P, Yueh A, Hsiao K-N, Lai L-W, Liu F-C, Chong P, Chen H-W (2009) A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect 11:288鈥?95 CrossRef
  26. McCloskey N, Turner MW, Goldblatt TD (1997) Correlation between the avidity of mouse-human chimeric IgG subclass monoclonal antibodies measured by solid-phase elution ELISA and biospecific interaction analysis (BIA). J Immunol Methods 205:67鈥?2 CrossRef
  27. Miller JL, de Wet BJ, Martinez-Pomares L, Radcliffe CM, Dwek RA, Rudd PM, Gordon S (2008) The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog 4:e17 CrossRef
  28. Modis Y, Ogata S, Clements D, Harrison SC (2004) Structure of the dengue virus envelope protein after membrane fusion. Nature 427:313鈥?19 CrossRef
  29. Morens DM (1994) Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis 19:500鈥?12 CrossRef
  30. Mota J, Acosta M, Argotte R, Figueroa R, Mendez A, Ramos C (2005) Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine 23:3469鈥?476 CrossRef
  31. Mukhopadhyay S, Kuhn RJ, Rossmann MG (2005) A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 3:13鈥?2 CrossRef
  32. Pan CH, Chen HW, Huang HW, Tao MH (2001) Protective mechanisms induced by a Japanese encephalitis virus DNA vaccine: requirement for antibody but not CD8(+) cytotoxic T-cell responses. J Virol 75:11457鈥?1463 CrossRef
  33. Pan CH, Valsamakis A, Colella T, Nair N, Adams RJ, Polack FP, Greer CE, Perri S, Polo JM, Griffin DE (2005) Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc Natl Acad Sci USA 102:11581鈥?1588 CrossRef
  34. Pan CH, Nair N, Adams RJ, Zink MC, Lee EY, Polack FP, Singh M, O鈥橦agan DT, Griffin DE (2008) Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques. Clin Vaccine Immunol 15:697鈥?06 CrossRef
  35. Putnak R, Fuller J, VanderZanden L, Innis BL, Vaughn DW (2003) Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-membrane and envelope genes. Am J Trop Med Hyg 68:469鈥?76
  36. Raviprakash K, Wang D, Ewing D, Holman DH, Block K, Woraratanadharm J, Chen L, Hayes C, Dong JY, Porter K (2008) A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. J Virol 82:6927鈥?934 CrossRef
  37. Rodriguez-Madoz JR, Belicha-Villanueva A, Bernal-Rubio D, Ashour J, Ayllon J, Fernandez-Sesma A (2010) Inhibition of the type I interferon response in human dendritic cells by dengue virus infection requires a catalytically active NS2B3 complex. J Virol 84:9760鈥?774 CrossRef
  38. Simmons M, Porter KR, Hayes CG, Vaughn DW, Putnak R (2006) Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J Virol 80:9577鈥?585 CrossRef
  39. Sitati EM, Diamond MS (2006) CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system. J Virol 80:12060鈥?2069 CrossRef
  40. Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, Johnson S, Rico-Hesse R, Harris E, Pierson TC, Fremont DH, Diamond MS (2010) Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol 84:9227鈥?239 CrossRef
  41. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, Trumpfheller C, Finke J, Sun W, Eller MA, Pattanapanyasat K, Sarasombath S, Birx DL, Steinman RM, Schlesinger S, Marovich MA (2003) DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 197:823鈥?29 CrossRef
  42. Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM (2009) Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392:103鈥?13 CrossRef
  43. White LJ, Parsons MM, Whitmore AC, Williams BM, de Silva A, Johnston RE (2007) An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice. J Virol 81:10329鈥?0339 CrossRef
  44. Whitehead SS, Falgout B, Hanley KA, Blaney Jr JE Jr, Markoff L, Murphy BR (2003) A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3鈥?untranslated region is highly attenuated and immunogenic in monkeys. J Virol 77:1653鈥?657
  45. Wu SF, Liao CL, Lin YL, Yeh CT, Chen LK, Huang YF, Chou HY, Huang JL, Shaio MF, Sytwu HK (2003) Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine 21:3919鈥?929 CrossRef
  46. Yauch LE, Prestwood TR, May MM, Morar MM, Zellweger RM, Peters B, Sette A, Shresta S (2010) CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J Immunol 185:5405鈥?416 CrossRef
  
• 作者单位：Hsin-Wei Chen (1) (2)
  Shih-Jen Liu (1) (2)
  Yi-Shiuan Li (1)
  Hsueh-Hung Liu (1)
  Jy-Ping Tsai (1)
  Chen-Yi Chiang (1)
  Mei-Yu Chen (1)
  Chyi-Sing Hwang (3)
  Chin-Cheng Huang (3)
  Hui-Mei Hu (1)
  Han-Hsuan Chung (1)
  Sze-Hsien Wu (1)
  Pele Chong (1)
  Chih-Hsiang Leng (1) (2)
  Chien-Hsiung Pan (1) (2)
  
  1. National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli, 350, Taiwan
  2. Graduate Institute of Immunology, China Medical University, Taichung, Taiwan
  3. Animal Health Research Institute, Council of Agriculture, 376 Chung-Cheng Road, Tamsui, Taipei, 251, Taiwan
  

文摘

We have previously demonstrated that vaccination with a subunit dengue vaccine containing a consensus envelope domain III with aluminum phosphate elicits neutralizing antibodies against all four serotypes of dengue virus in mice. In this study, we evaluated the immunogenicity of the subunit dengue vaccine in non-human primates. After vaccination, monkeys that received the subunit vaccine with aluminum phosphate developed a significantly strong and long-lasting antibody response. A specific T cell response with cytokine production was also induced, and this correlated with the antibody response. Additionally, neutralizing antibodies against serotype 2 were detected in two of three monkeys. The increase in serotype-2-specific antibody titers and avidity observed in these two monkeys suggested that a serotype-2-biased antibody response occurs. These data provide evidence that a protective neutralizing antibody response was successfully elicited in non-human primates by the dengue subunit vaccine with aluminum phosphate adjuvant.